


## Amendments to the claims:

1. (Currently amended) A method for treating a subject with an allergic condition, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I) below:



wherein:

$R^1$  is hydrogen, azido, halogen,  $C_{1-5}$  alkoxy, hydroxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^7R^8N$ ,  $C_{2-8}$  acyl,  $R^9OC=O$ ,  $R^{10}R^{11}NC=O$ , or  $R^{10}R^{11}NSO_2$ ; or  $R^1$  is taken together with  $W$  as described below;

$R^2$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl,  $C_{1-5}$  haloalkyl, cyano, or  $R^{48}R^{49}N$ ; alternatively,  $R^1$  and  $R^2$  can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;

each of  $R^3$  and  $R^4$  is independently hydrogen or  $C_{1-5}$  alkyl;

each of  $R^5$  and  $R^6$  is independently hydrogen,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkylthio, halogen, or a 4-7 membered carbocyclyl or heterocyclyl;

$R^{40}$  is ~~H,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, benzyl, phenethyl,  $C_{1-5}$  heterocyclyl, ( $C_{1-5}$  heterocyclyl) $C_{1-5}$  alkylene, amino, or mono- or di( $C_{1-5}$  alkyl)amino, or  $R^{68}OR^{59}$ , wherein  $R^{68}$  is  $H$ ,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, benzyl, phenethyl,  $C_{1-5}$  heterocyclyl, or ( $C_{1-5}$  heterocyclyl) $C_{1-5}$  alkylene and  $R^{69}$  is  $C_{1-5}$  alkylene, phenylene, or divalent  $C_{1-5}$  heterocyclyl; and~~

$R^{62}$  can be  $H$  in addition to the values for  $R^{40}$ ;

$R^7$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{27}OC=O$ ,  $R^{28}R^{29}NC=O$ ,  $R^{27}SO$ ,  $R^{27}SO_2$ , or  $R^{28}R^{29}NSO_2$ ;

$R^8$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^7$  and  $R^8$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

$R^9$  is  $C_{1-5}$  alkyl, phenyl, naphthyl, or  $C_{1-5}$  heterocyclyl;

$R^{21}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{30}OC=O$ ,  $R^{31}R^{32}NC=O$ ,  $R^{30}SO$ ,  $R^{30}SO_2$ , or  $R^{31}R^{32}NSO_2$ ;

$R^{22}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^{21}$  and  $R^{22}$  can be taken together to form an optionally substituted 4- to 7-membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

each of  $R^{23}$ ,  $R^{26}$ ,  $R^{27}$ ,  $R^{30}$ ,  $R^{33}$ ,  $R^{44}$ ,  $R^{45}$ , and  $R^{50}$  is  $C_{1-5}$  alkyl, phenyl, naphthyl, or  $C_{1-5}$  heterocyclyl;

$R^{24}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{33}OC=O$ ,  $R^{34}R^{35}NC=O$ ,  $R^{33}SO$ ,  $R^{33}SO_2$ , or  $R^{34}R^{35}NSO_2$ ;

$R^{25}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^{24}$  and  $R^{25}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

each of  $R^{10}$  and  $R^{11}$  is independently hydrogen,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^{10}$  and  $R^{11}$  or can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

each of  $R^{28}$ ,  $R^{29}$ ,  $R^{31}$ ,  $R^{32}$ ,  $R^{34}$ ,  $R^{35}$ ,  $R^{46}$ ,  $R^{47}$ ,  $R^{51}$  and  $R^{52}$  is independently hydrogen,  $C_{1-5}$  alkyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^{28}$  and  $R^{29}$ ,  $R^{31}$  and  $R^{32}$ ,  $R^{34}$  and  $R^{35}$ ,  $R^{46}$  and  $R^{47}$ , or  $R^{51}$  and  $R^{52}$ , independently, can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be

saturated, unsaturated or aromatic;

n is 1;

G represents  $C_{3-6}$  alkenediyyl or  $C_{3-6}$  alkanediyyl, optionally substituted with hydroxy, halogen,  $C_{1-5}$  alkyl,  $C_{1-5}$  alkoxy, oxo, hydroximino,  $CO_2R^{60}$ ,  $R^{60}R^{61}NCO_2$ , (L)- $C_{1-4}$  alkylene-, (L)- $C_{1-5}$  alkoxy,  $N_3$ , or [(L)- $C_{1-5}$  alkylene]amino; each of  $R^{60}$  and  $R^{61}$  is independently hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, benzyl, phenethyl, or  $C_{1-5}$  heterocyclyl; alternatively  $R^{60}$  and  $R^{61}$ , can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

L is amino, mono- or di- $C_{1-5}$  alkylamino, pyrrolidinyl, morpholinyl, piperidinyl homopiperidinyl, or piperazinyl, where available ring nitrogens may be optionally substituted with  $C_{1-5}$  alkyl, benzyl,  $C_{2-5}$  acyl,  $C_{1-5}$  alkylsulfonyl or  $C_{1-5}$  alkylloxycarbonyl;

X is nitrogen or  $R^{12}C$ ;

Y is nitrogen or  $R^{13}C$ ;

Z is nitrogen or  $R^{14}C$ ;

$R^{12}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^{21}R^{22}N$ ,  $C_{2-8}$  acyl,  $C_{1-5}$  haloalkyl,  $C_{1-5}$  heterocyclyl, ( $C_{1-5}$  heterocyclyl) $C_{1-5}$  alkylene,  $R^{23}OC=O$ ,  $R^{23}O(C=O)NH-$ ,  $R^{23}SO$ ,  $R^{22}NHCO-$ ,  $R^{22}NH(C=O)NH-$ ,  $R^{23}(C_{1-4}$  alkylene) $NHCO-$ ,  $R^{23}SO_2$ , or  $R^{23}SO_2NH-$ ;

$R^{13}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^{42}R^{43}N$ ,  $C_{2-8}$  acyl,  $C_{1-5}$  haloalkyl,  $C_{1-5}$  heterocyclyl, ( $C_{1-5}$  heterocyclyl) $C_{1-5}$  alkylene,  $R^{44}OC=O$ ,  $R^{44}O(C=O)NH-$ ,  $R^{44}SO$ ,  $R^{43}NHCO-$ ,  $R^{43}NH(C=O)NH-$ ,  $R^{44}(C_{1-4}$  alkylene) $NHCO-$ ,  $R^{44}SO_2$ , or  $R^{44}SO_2NH-$ ;

$R^{14}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^{24}R^{25}N$ ,  $C_{2-8}$  acyl,  $C_{1-5}$  haloalkyl,  $C_{1-5}$  heterocyclyl, ( $C_{1-5}$  heterocyclyl) $C_{1-5}$  alkylene,  $R^{26}OC=O$ ,  $R^{26}O(C=O)NH-$ ,  $R^{26}SO$ ,  $R^{25}NHCO-$ ,  $R^{25}NH(C=O)NH-$ ,  $R^{26}(C_{1-4}$  alkylene) $NHCO-$ ,  $R^{26}SO_2$ , or  $R^{26}SO_2NH-$ ; alternatively,  $R^{12}$  and  $R^{13}$  or  $R^{12}$  and  $R^2$  or  $R^{13}$  and  $R^{14}$  can be taken together to form an optionally substituted 5- to 6- membered carbocyclic or

heterocyclic ring, which ring may be unsaturated or aromatic;

Ar represents a monocyclic or bicyclic aryl or heteroaryl ring, optionally substituted with between 1 and 3 substituents selected from halogen, C<sub>1-5</sub> alkoxy, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, cyano, azido, nitro, R<sup>15</sup>R<sup>16</sup>N, R<sup>17</sup>SO<sub>2</sub>, R<sup>17</sup>S, R<sup>17</sup>SO, R<sup>17</sup>OC=O, R<sup>15</sup>R<sup>16</sup>NC=O, C<sub>1-5</sub> haloalkyl, C<sub>1-5</sub> haloalkoxy, C<sub>1-5</sub> haloalkylthio, and C<sub>1-5</sub> alkylthio;

R<sup>15</sup> is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, benzyl, C<sub>1-5</sub> heterocyclyl, C<sub>2-8</sub> acyl, aroyl, R<sup>53</sup>OC=O, R<sup>54</sup>R<sup>55</sup>NC=O, R<sup>53</sup>S, R<sup>53</sup>SO, R<sup>53</sup>SO<sub>2</sub>, or R<sup>54</sup>R<sup>55</sup>NSO<sub>2</sub>;


R<sup>16</sup> is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, benzyl, or C<sub>1-5</sub> heterocyclyl; alternatively, R<sup>15</sup> and R<sup>16</sup> can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

each of R<sup>17</sup> and R<sup>53</sup> is C<sub>1-5</sub> alkyl, phenyl, or C<sub>1-5</sub> heterocyclyl;


each of R<sup>54</sup> and R<sup>55</sup> is independently hydrogen, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, phenyl, benzyl, or C<sub>1-5</sub> heterocyclyl;

alternatively, R<sup>54</sup> and R<sup>55</sup> can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

W represents SO<sub>2</sub>, C=O, CHR<sup>20</sup>, or a covalent bond; or W and R<sup>1</sup>, taken together with the 6-membered ring to which they are both attached, form one of the following two formulae:



(I)(a)



(I)(b)

wherein X<sub>a</sub> is O, S, or N; and X<sub>b</sub> is O, S or SO<sub>2</sub>;

R<sup>20</sup> is hydrogen, C<sub>1-5</sub> alkyl, phenyl, benzyl, naphthyl, or C<sub>1-5</sub> heterocyclyl;

$R^{42}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{45}OC=O$ ,  $R^{46}R^{47}NC=O$ ,  $R^{45}SO$ ,  $R^{45}SO_2$ , or  $R^{46}R^{47}NSO_2$ ;

$R^{43}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^{42}$  and  $R^{43}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

$R^{44}$  is  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, naphthyl, or  $C_{1-5}$  heterocyclyl;

$R^{48}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, naphthyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{50}OC=O$ ,  $R^{51}R^{52}NC=O$ ,  $R^{50}SO$ ,  $R^{50}SO_2$ , or  $R^{51}R^{52}NSO_2$ ;

$R^{49}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, or  $C_{1-5}$  heterocyclyl; alternatively,  $R^{48}$  and  $R^{49}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; and

wherein each of the above hydrocarbyl or heterocarbyl groups, unless otherwise indicated, and in addition to any specified substituents, is optionally and independently substituted with between 1 and 3 substituents selected from methyl, halomethyl, hydroxymethyl, halo, hydroxy, amino, nitro, cyano,  $C_{1-5}$  alkyl,  $C_{1-5}$  alkoxy,  $-COOH$ ,  $C_{2-6}$  acyl,  $[di(C_{1-4} \text{ alkyl})\text{amino}]C_{2-5}$  alkylene,  $[di(C_{1-4} \text{ alkyl})\text{amino}]C_{2-5}$  alkyl- $NH-CO-$ , and  $C_{1-5}$  haloalkoxy;

or a pharmaceutically acceptable salt, ester, or amide thereof.

2. (Previously presented) A method of claim 1, wherein each of  $R^3$  and  $R^4$  is hydrogen; Ar represents a six membered ring, optionally substituted with between 1 and 2 substituents selected from halogen,  $C_{1-5}$  alkyl, cyano, nitro,  $R^{15}R^{16}N$ ,  $CF_3$  and  $OCF_3$ ;  $R^{12}$  is hydrogen,  $R^{23}SO$ , or  $R^{23}SO_2$ ;  $R^{13}$  is hydrogen,  $R^{44}SO$ , or  $R^{44}SO_2$ ;  $R^{14}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl, cyano, nitro, or  $R^{24}R^{25}N$ ; and G is  $C_3$  alkanediyl, optionally substituted with hydroxy, (L)- $C_{1-5}$  alkoxy-, or (L)- $C_{1-5}$  alkylamino.

3. (Previously presented) A method of claim 2, wherein Ar is phenyl.

4. (Canceled)

5. (Canceled)

6. (Previously presented) A method of claim 1, wherein said compound is:

1-[3-(3,4-Dichloro-phenyl)-pyrazol-1-yl]-3-(4-o-tolyl-piperazin-1-yl)-propan-2-ol.

7. (Canceled)

8. (Previously presented) A method of claim 1, wherein said pharmaceutical composition is formulated in a dosage amount appropriate for the treatment of an allergic condition.
9. (Previously presented) A method of claim 1, wherein said condition is asthma.
10. (Previously presented) A method of claim 2, wherein said condition is asthma.
11. (Previously presented) A method of claim 3, wherein said condition is asthma.
12. (Currently amended) A method of claim [[7]]6, wherein said condition is asthma.